Deal watch: dipping into Incyte's JAK-pot.

摘要

Incyte has entered into two large licensing deals for their JAK1/JAK2 inhibitors INCB28050 and INCB18424. In late December 2009, the worldwide rights to INCB28050, which is in mid-stage trials for rheumatoid arthritis, were acquired by Eh Lilly for USDollars 90 million upfront, with up to Dollars 665 million in potential milestone payments. This followed soon after a deal in which Novartis acquired ex-US rights to INCB18424- which is in Phase III trials for myelofibrosis- as well as the MET inhibitor INCB28060, for dollar150 million upfront and up to dollar1.1 billion in potential milestone payments.